



### Afinitor<sup>®</sup> (everolimus) – First-time generic

- On December 10, 2019, [Par](#) launched an [AB-rated](#) generic version of Novartis' [Afinitor \(everolimus\)](#) 2.5 mg, 5 mg, and 7.5 mg tablets.
  - Teva received FDA approval of an [AB-rated](#) generic version of Afinitor 2.5 mg, 5 mg, 7.5 mg and 10 mg tablets on December 9, 2019. Launch plans are pending.
- Afinitor is approved for the treatment of hormone receptor-positive, HER2-negative breast cancer; neuroendocrine tumors; renal cell carcinoma; tuberous sclerosis complex (TSC)-associated renal angiomyolipoma; and TSC-associated subependymal giant cell astrocytoma.
- Afinitor is also available as a brand 10 mg tablet and oral tablets for suspension (Afinitor Disperz).
  - Afinitor Disperz is approved for the treatment of TSC-associated subependymal giant cell astrocytoma and TSC-associated partial-onset seizures.
- According to IQVIA, sales for Afinitor 2.5 mg, 5 mg and 7.5 mg tablets were approximately \$412 million over the last four quarters.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.